5-甲氧基-2-甲基苯-1,3-二醇 | 6307-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 5-甲氧基-2-甲基苯-1,3-二醇
• 英文名称: 2,6-dihydroxy-4-methoxytoluene
• 英文别名: 5-methoxy-2-methyl-resorcinol；5-Methoxy-2-methyl-resorcin；Methyl-(3.5-dihydroxy-4-methyl-phenyl)-aether；2.6-Dihydroxy-4-methoxy-toluol；2.6-Dioxy-4-methoxy-toluol；2.6-Dioxy-4-methoxy-1-methyl-benzol；5-Methoxy-2-methylbenzene-1,3-diol
• CAS: 6307-89-7
• 化学式: C₈H₁₀O₃
• 分子量: 154.166
• InChiKey: YPIDZFLQKNEKRA-UHFFFAOYSA-N

物化性质

• 碰撞截面：
  127.1 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-甲氧基-2-甲基苯-1,3-二醇 在 aluminum (III) chloride 、 对甲苯磺酰氯 作用下， 以 氯仿 、 硝基苯 为溶剂， 反应 2.5h， 生成 2,4,2',4'-Tetraoxy-6,6'-dimethoxy-3,3'-dimethyl-5,5'-diisobutyryl-diphenylmethan
  参考文献：
  名称：

  天然产物Ivesinol及其衍生物的合成方法与应用

  摘要：

  本发明公开了天然产物Ivesinol及其衍生物的合成方法与应用，所述方法包括如下步骤：化合物12，4，6‑三羟基苯甲醛经甲基化、醛基还原反应制得化合物3，化合物3通过傅克酰基化反应得到化合物4；化合物5间苯三酚经甲基化、傅克反应制得化合物7，化合物7通过Vilsmeier反应引入醛基，将醛基还原即得到化合物9；化合物4和9通过偶联反应得到化合物IVE‑1和/或IVE‑2，即天然产物Ivesinol及其衍生物；本发明通过逆合成分析，以商业化试剂为起始原料，探索并完成了天然产物Ivesinol及其衍生物的全合成路线，构建了Ivesinol衍生物的系列化合物库，为进一步探究该天然产物及其衍生物的构效关系，研究此类化合物的抗菌活性和成药性打下了基础，对治疗耐药菌引起的感染性疾病具有重要意义。

  公开号：

  CN117024262A
• 作为产物：
  描述：

  4-氨基-2,6-二硝基甲苯 在 盐酸 、 氢氧化钾 、 tin 、 硫酸 作用下， 生成 5-甲氧基-2-甲基苯-1,3-二醇
  参考文献：
  名称：

  114.松萝酸。第一部分：甲基间苯三酚的衍生物

  摘要：

  DOI：

  10.1039/jr9330000437

文献信息

• NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
  申请人：Calvet James P.

  公开号：US20110082098A1

  公开（公告）日：2011-04-07

  Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.

  新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病（ADPKD）中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法，包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平，或其组合。此外，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平，或其组合。
• INFLAMMATORY CYTOKINE RELEASE INHIBITOR
  申请人：MUTO Susumu

  公开号：US20090192122A2

  公开（公告）日：2009-07-30

  A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.

  一种具有抑制NF-κB激活活性的药物，其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分：其中X代表连接基，A代表氢原子或乙酰基，E代表芳基或杂芳基，环X代表芳烃或杂芳烃。
• Cytotoxic Agents Comprising New Tomaymycin Derivatives
  申请人：GAUZY Laurence

  公开号：US20090036431A1

  公开（公告）日：2009-02-05

  The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.

  本发明涉及新的托马霉素衍生物，它们的制备过程及其治疗用途。
• ANTIALLERGIC AGENTS
  申请人：Muto Susumu

  公开号：US20080090779A1

  公开（公告）日：2008-04-17

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X表示连接基，其主链中原子数为2至5（该连接基可以被取代），A表示氢原子或乙酰基，E表示芳基或取代的杂芳基，环Z表示苯环，除了由公式-O-A表示的基团，该苯环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同，或者是一个杂环，除了由公式-O-A表示的基团，该杂环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同。
• Antiallergic agents
  申请人：Muto Susumu

  公开号：US20070185059A1

  公开（公告）日：2007-08-09

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其活性成分包括以下通式（I）表示的化合物或其药学上可接受的盐、水合物和溶剂化物中的一种，其中X代表连接基，其主链中的原子数为2到（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂环芳基，环Z代表芳烃，除了由公式-O-A表示的基团外，还可以有一个或多个取代基，其中A具有上述定义的相同含义，并且由公式-X-E表示的基团，其中X和E的每个都具有上述定义的相同含义，或者可以有一个或多个取代基的杂芳烃，其中A具有上述定义的相同含义，并且由公式-X-E表示的基团，其中X和E的每个都具有上述定义的相同含义。